Family · Pharmaceutical analytical standards
Revefenacin
A long-acting muscarinic antagonist (LAMA) bronchodilator, approved in the United States in 2018 for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It was the first once-daily nebulised bronchodilator for COPD: it is inhaled with a standard jet nebuliser rather than a handheld inhaler.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
